About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Response and Safety Following FMT for UC | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT04294615

Clinical Response and Safety Following FMT for UC

The study aims to evaluate the clinical efficacy and safety of fecal microbiota transplantation by automatic methods in the treatment of moderate to severe active ulcerative colitis. There are two gro...

Lead sponsor: Air Force Military Medical University, China•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Air Force Military Medical University, China

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\- Eligible patients required a diagnosis of ulcerative colitis made by a primary gastroenterologist based upon history, physical exam, laboratory/radiological studies and gastrointestinal histology. All patients were age ≥ 18 year old at the time of enrollment. They had moderate to severe symptoms with a mayo score between 6\~12 and an endoscopic subscore ≥2. Patient medication for UC could not have changed for at least one month prior to FMT.

Exclusion Criteria

•\- Active or history of intraabdominal abscess, acute abdomen or other clinical emergencies requiring emergent management, pregnancy, prior history of FMT, prior history of TNF inhibitors use, or other serious systemic disease.

Related studies

RECRUITINGPhase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

RECRUITINGPhase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

RECRUITINGPhase 2/3

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

NCT05986136 · Inflammatory Bowel Diseases

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

NCT06266663 · Inflammatory Bowel Diseases

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

NCT05332639 · Inflammatory Bowel Diseases, Crohn Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 4, 2020Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment9

Start dateApr 2016

Last updatedMar 4, 2020

Condition

Inflammatory Bowel Diseases Fecal Microbiota Transplantation

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions